Business Overview: LeonaBio, Inc. (Nasdaq: LONA)

---

Executive Summary

LeonaBio, Inc. (formerly Athira Pharma, Inc., which changed its name and ticker from ATHA/Athira to LONA/LeonaBio in early 2026) is a Seattle-area clinical-stage biopharmaceutical company developing therapies for high-unmet-need diseases, now spanning both neurology and oncology. Its pipeline centers on ATH-1105, an internally developed, brain-penetrant small molecule for amyotrophic lateral sclerosis (ALS), and lasofoxifene, a late-stage oral selective estrogen receptor modulator (SERM) for ESR1-mutated metastatic breast cancer that LeonaBio in-licensed in December 2025 to diversify beyond its legacy, since-discontinued Alzheimer's program.

LeonaBio matters as a case study in biotech pipeline reinvention: after its original lead Alzheimer's candidate (fosgonimeton) failed to show efficacy, the company pivoted its remaining cash and management toward a combination of an in-house neurology asset and an in-licensed, later-stage oncology asset — while facing real liquidity constraints along the way.

---

1. Core Business Model & How They Work

As a clinical-stage biopharmaceutical company, LeonaBio generates no product revenue today. Its model is the standard biotech value-creation cycle: advance drug candidates through clinical trials toward approval or partnership, funded by equity and licensing capital rather than sales.

[ Discovery / In-Licensing ] ⇒ [ Preclinical & Phase 1 Safety ] ⇒ [ Phase 2 / Phase 3 Efficacy Trials ] ⇒ [ Regulatory Filing (FDA) ] ⇒ [ Commercialization or Partnership ]

Key Operational Drivers

1. Pipeline diversification via in-licensing: the December 2025 lasofoxifene deal (rights from Sermonix and Ligand) added a later-stage oncology asset to reduce reliance on the earlier-stage ALS program alone.
2. Capital-light manufacturing: LeonaBio uses third-party contract development and manufacturing organizations (CDMOs) rather than owning production facilities.
3. Regulatory designations as validation: lasofoxifene holds FDA Fast Track Designation (granted 2019), intended to speed development and review.
4. Going-concern funding pressure: the company has stated it will require substantial additional funding, and a late Form 8-K filing has made it temporarily ineligible to use the shelf-registration Form S-3, constraining some financing options.

---

2. Business Segments

LeonaBio operates as a single clinical-stage biopharmaceutical business; it does not report distinct operating segments. Its pipeline instead spans two therapeutic areas, described in the Product Portfolio below.

---

3. Product Portfolio

---

4. Competitive Landscape

• Oncology (ESR1-mutated metastatic breast cancer): LeonaBio names Menarini Group (Orserdu), Eli Lilly (Inluriyo), AstraZeneca, Arvinas, Olema, and F. Hoffmann-La Roche as competitors targeting the same ESR1-mutant, post-CDK4/6-inhibitor patient population.
• ALS (HGF/MET pathway): Prior attempts in this mechanism — Helixmith (VM202) and Kringle Pharma (KP-100) — both failed to reach statistically significant efficacy in Phase 2, underscoring both the opportunity and the scientific risk ATH-1105 faces.

      DEVELOPMENT STAGE vs. COMPETITIVE CROWDING
   ┌───────────────────────────────────────────────┐
   │ Crowded  │         [Lilly, AZ, Menarini]         │
   │          │    (approved/later-stage oncology)    │
   │          │                                        │
   │          │   [LeonaBio - Lasofoxifene]            │
   │          │        (Phase 3)                       │
   │ Sparse   │  [LeonaBio - ATH-1105]                 │
   │          │   (Phase 1 done; failed precedents:    │
   │          │    Helixmith, Kringle)                 │
   └───────────────────────────────────────────────┘
      Early Stage                      Late Stage

---

5. Strategic Strengths & Risks

Strengths (Moat Sources)

• FDA Fast Track Designation for lasofoxifene, which can speed regulatory review if trials succeed.
• Pipeline diversification away from a single, now-failed neurology program toward two distinct, higher-potential assets.
• Capital-light CDMO manufacturing model, avoiding fixed manufacturing overhead during the clinical stage.
• Meaningful Phase 3 enrollment progress on lasofoxifene (>50% as of December 2025), reducing (but not eliminating) execution risk on the most advanced program.

Risks

• No approved products and no Phase 3 completions: the company has never brought a drug through full Phase 3 and FDA approval.
• Liquidity constraints: media coverage and company disclosures describe the company facing liquidity constraints following its strategic oncology pivot, and the filing states it "will require substantial additional funding."
• Financing limitations: a late Form 8-K filing has made the company temporarily ineligible to use Form S-3, a common, lower-friction capital-raising tool.
• Clinical/scientific risk: the HGF/MET mechanism behind ATH-1105 has twice failed in Phase 2 trials run by other companies (Helixmith, Kringle Pharma).
• Governance/stock risk: the filing discloses litigation involving the company and its officers/directors and activist stockholder involvement.

---

6. Financial Overview

---

7. Summary Conclusion

LeonaBio is a story of biotech reinvention under pressure: a failed Alzheimer's bet forced a pivot into a later-stage, in-licensed oncology asset (lasofoxifene) alongside an earlier, internally discovered ALS program (ATH-1105). The lasofoxifene Phase 3 readout expected in the second half of 2027 is the single most important near-term catalyst, but the company's own disclosed liquidity constraints and temporary loss of Form S-3 eligibility mean financing risk, not just clinical risk, will determine whether it reaches that readout on its own terms.